BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 8138825)

  • 1. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.
    Ott M; Demisch L; Engelhardt W; Fischer PA
    J Neurol; 1993 Dec; 241(2):108-14. PubMed ID: 8138825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility.
    Peter JB; Boctor FN; Tourtellotte WW
    Neurology; 1991 Jan; 41(1):121-3. PubMed ID: 1985276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
    Hofmann B; Bass H; Nishanian P; Faisal M; Figlin RA; Sarna GP; Fahey JL
    Clin Exp Immunol; 1992 Jun; 88(3):548-54. PubMed ID: 1606739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.
    Shaw CE; Dunbar PR; Macaulay HA; Neale TJ
    J Neurol; 1995 Jan; 242(2):53-8. PubMed ID: 7707089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
    Clements PJ; Peter JB; Agopian MS; Telian NS; Furst DE
    J Rheumatol; 1990 Jul; 17(7):908-10. PubMed ID: 2213757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
    Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
    Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased levels of beta 2-microglobulin, soluble interleukin-2 receptor, and soluble CD8 in patients with subacute sclerosing panencephalitis.
    Mehta PD; Kulczycki J; Mehta SP; Sobczyk W; Coyle PK; Sersen EA; Wisniewski HM
    Clin Immunol Immunopathol; 1992 Oct; 65(1):53-9. PubMed ID: 1382909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum levels of soluble interleukin-2 receptor, neopterin and beta-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis.
    Caforio AL; Goldman JH; Baig MK; Mahon NJ; Haven AJ; Souberbielle BE; Holt DW; Dalgleish AG; McKenna WJ
    Eur J Heart Fail; 2001 Mar; 3(2):155-63. PubMed ID: 11246052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls.
    Sivieri S; Ferrarini AM; Gallo P
    Mult Scler; 1998 Feb; 4(1):7-11. PubMed ID: 9532585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis.
    Fredrikson S; Eneroth P; Link H
    Clin Exp Immunol; 1987 Jan; 67(1):76-81. PubMed ID: 3621676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis.
    Freedman MS; Muth KL; Trotter JL; Yoshizawa CN; Antel JP
    Neurology; 1992 Aug; 42(8):1596-601. PubMed ID: 1641157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
    Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of soluble interleukin-2, soluble interleukin-2 receptors, soluble ICAM-1 and beta 2-microglobulin in breast cancer patients.
    Klein B; Levin I; Kfir B; Mishaeli M; Shapira J; Klein T
    Tumour Biol; 1995; 16(5):290-6. PubMed ID: 7652467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers for cell-mediated immune response are elevated in cerebrospinal fluid and serum after severe traumatic brain injury in humans.
    Lenzlinger PM; Hans VH; Jöller-Jemelka HI; Trentz O; Morganti-Kossmann MC; Kossmann T
    J Neurotrauma; 2001 May; 18(5):479-89. PubMed ID: 11393251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neopterin, soluble interleukin-2 receptor and adenosine deaminase levels in pleural effusions.
    Chiang CS; Chiang CD; Lin JW; Huang PL; Chu JJ
    Respiration; 1994; 61(3):150-4. PubMed ID: 8047718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients.
    Durastanti V; Lugaresi A; Bramanti P; Amato M; Bellantonio P; De Luca G; Picconi O; Fantozzi R; Locatelli L; Solda' A; Sessa E; Totaro R; Marino S; Zipoli V; Zorzon M; Millefiorini E
    J Transl Med; 2011 Apr; 9():42. PubMed ID: 21501517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
    Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
    J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
    Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
    J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.